Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Status:
Terminated
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well carfilzomib with or without rituximab work in treating
patients with Waldenstrom macroglobulinemia or marginal zone lymphoma that is previously
untreated, has come back, or does not respond to treatment. Carfilzomib may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with
monoclonal antibodies, such as rituximab, may induce changes in body's immune system and may
interfere with the ability of tumor cells to grow and spread. Giving carfilzomib alone when
disease is responding or with rituximab when disease is not responding may work better in
treating patients with Waldenstrom macroglobulinemia or marginal zone lymphoma.